The in vitro MIMIC® platform reflects age-associated changes in immunological responses after influenza vaccination

Highlights • MIMIC® sys tem is a fully human in vitro model for testing vaccine immunogenicity. • In vitro MIMIC® recapitulates in vivo flu-specific immune responses in same cohort. • MIMIC® system shows reduced flu-specific B and T cell responses in elderly donors. • MIMIC® system reflects the role...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2017-10, Vol.35 (41), p.5487-5494
Hauptverfasser:	Dauner, Allison, Agrawal, Pankaj, Salvatico, Jose, Tapia, Tenekua, Dhir, Vipra, Shaik, S. Farzana, Drake, Donald R, Byers, Anthony M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive immunity Adaptive Immunity - immunology Adult Adults Age Aged Aged, 80 and over Allergy and Immunology Antibodies Antibodies, Viral - immunology Antigens B-Lymphocytes - immunology CD4 antigen CD4-Positive T-Lymphocytes - immunology CD40L protein Cell activation Critical path Cytokines Elderly Expenditures Female Geriatrics Human Human performance Humans Immunity, Innate - immunology Immunogenicity Immunoglobulin G Immunoglobulin G - immunology Immunoglobulins Immunology Immunomodulation Immunosenescence In vitro Influenza Influenza Vaccines - immunology Influenza, Human - immunology Interleukin 2 Interleukin-2 - immunology Lymphocyte Activation - immunology Lymphocytes Lymphocytes B Lymphocytes T Male Middle Aged MIMIC Older people R&D Reduction Research & development Vaccination - methods Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • MIMIC® sys tem is a fully human in vitro model for testing vaccine immunogenicity. • In vitro MIMIC® recapitulates in vivo flu-specific immune responses in same cohort. • MIMIC® system shows reduced flu-specific B and T cell responses in elderly donors. • MIMIC® system reflects the role of donor-intrinsic factors on the immune response.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2017.03.099